IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET
2023年9月8日 - 5:30AM
IMUNON,
Inc. (Nasdaq:
IMNN), a clinical-stage
biotechnology company focused on developing DNA-mediated
immunotherapy and next-generation vaccines, announces that it will
hold a virtual R&D Day event on September 14th beginning at
4:00 p.m. Eastern time. Details about speakers and instructions on
how to participate are below.
The Event’s Speakers
IMUNON presenters include:
- Dr. Corinne Le Goff, President and
Chief Executive Officer
- Khursheed Anwer, Ph.D., Executive
Vice President and Chief Science Officer
Guest key opinion leader presenters include:
- Sallie Permar, M.D., Ph.D., Chair
of the Department of Pediatrics at Weill Cornell Medicine and
Pediatrician-in-Chief at New York-Presbyterian/Weill Cornell
Medical Center and New York-Presbyterian Komansky Children’s
Hospital. She is also Nancy C. Paduano Professor and Chair, Weill
Cornell Medicine.
- Patrick Ott, M.D., Ph.D., Clinical
Director of the Melanoma Disease Center and the Director, Clinical
Sciences, of the Center for Immuno-Oncology at the Dana-Farber
Cancer Institute. He is also an attending physician in the
Department of Medicine at Brigham and Women's Hospital and is an
Associate Professor at Harvard Medical School.
Dr. Permar will focus her presentation on the
“Vaccines of the Future” while Dr. Ott will discuss
“Immuno-Oncology: The remaining unmet need.”
Dr. Permar is a physician-scientist focusing on
the prevention and treatment of neonatal viral infections and leads
a research laboratory investigating immune protection against
vertical transmission of neonatal viral pathogens, namely HIV and
cytomegalovirus. Dr. Ott is a clinical investigator and a member of
the clinical trials program at Dana Farber/Harvard Cancer Center,
where he designs and conducts Phase 1 immunotherapy trials for
patients with melanoma and other tumors.
How to
Participate
The virtual program will be held online
beginning at 4:00 p.m. Eastern Time and is expected to last
approximately 90 minutes. There is no need to pre-register for the
event. A live and archived webcast will be available in the
Scientific Presentations section of IMUNON’s website. Following
management’s presentations, a Q&A session will be available via
the chat function of the webcast.
About IMUNON
IMUNON is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies.
IMUNON has two platform technologies: the
TheraPlas modality for the development of immunotherapies and other
anti-cancer nucleic acid-based therapies, and the PlaCCine modality
for the development of nucleic acid vaccines for infectious
diseases and cancer. The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting preclinical proof-of-concept studies on a nucleic acid
vaccine candidate (IMNN-101) targeting the SARS-CoV-2 virus to
validate its PlaCCine platform. IMUNON’s platform technologies are
based on the delivery of nucleic acids with novel synthetic
delivery systems that are independent of viral vectors or devices.
IMUNON will continue to leverage these platforms and to advance the
technological frontier of nucleic acid-based products to better
serve patients with difficult-to-treat conditions. For more
information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey
W. Church |
Kim
Sutton Golodetz |
Executive
Vice President, CFO |
212-838-3777 |
and
Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024